Literature DB >> 11562742

Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.

Y H Choi1.   

Abstract

The breast and ovarian cancer susceptibility gene BRCA1 encodes a nuclear phosphoprotein, which functions as a tumor suppressor gene. We present several lines of evidence for the mechanism of BRCA1 degradation through the ubiquitin-proteasome pathway by using specific inhibitors of the proteasome in human MCF-7 breast carcinoma cells. The levels of BRCA1 protein were up-regulated by proteasome inhibitors, such as MG-132 and ALLnL, suggesting rapid degradation via the ubiquitin-proteasome pathway. The enhanced loss of BRCA1 protein by taxol, okadaic acid or nocodazole treatment was prevented by the proteasome inhibitors, while inhibition of other proteases was ineffective. Accumulation and proteasomal degradation of BRCA1 protein appear to be restricted entirely to the nucleus. We also detected that high molecular weight BRCA1 protein species appeared after proteasome inhibitor treatments, which indicated that ubiquitinated species were present. Moreover the half-life of BRCA1 protein was significantly increased in response to inhibition of proteasome activity. Our present data demonstrate that BRCA1 protein may be degraded through the ubiquitin-proteasome mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562742

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  The C-terminal proteolytic fragment of the breast cancer susceptibility type 1 protein (BRCA1) is degraded by the N-end rule pathway.

Authors:  Zhizhong Xu; Roshani Payoe; Richard P Fahlman
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

2.  Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma.

Authors:  Jing-Yi Guo; Zuo-Qian Jing; Xue-Jie Li; Li-Yuan Liu
Journal:  Int J Med Sci       Date:  2022-05-01       Impact factor: 3.642

3.  Ubiquitin pathway and ovarian cancer.

Authors:  Z Rao; Y Ding
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

4.  Turnover of BRCA1 involves in radiation-induced apoptosis.

Authors:  Weijun Liu; Wenjun Zong; George Wu; Takeo Fujita; Wenqi Li; Judy Wu; Yong Wan
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

5.  Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.

Authors:  Fabian Dominik Mairinger; Robert Fred Henry Walter; Dirk Theegarten; Thomas Hager; Claudia Vollbrecht; Daniel Christian Christoph; Karl Worm; Saskia Ting; Robert Werner; Georgios Stamatis; Thomas Mairinger; Hideo Baba; Konstantinos Zarogoulidis; Haidong Huang; Qiang Li; Kosmas Tsakiridis; Paul Zarogoulidis; Kurt Werner Schmid; Jeremias Wohlschlaeger
Journal:  J Cancer       Date:  2014-08-01       Impact factor: 4.207

6.  USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.

Authors:  Qin Lu; Fang-Lin Zhang; Da-Yun Lu; Zhi-Ming Shao; Da-Qiang Li
Journal:  Cancer Med       Date:  2019-09-11       Impact factor: 4.452

7.  The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.

Authors:  Yan Wang; Ziliang Wang; Zihao Qi; Sheng Yin; Na Zhang; Yang Liu; Mingming Liu; Jiao Meng; Rongyu Zang; Zhen Zhang; Gong Yang
Journal:  Mol Cancer       Date:  2014-04-28       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.